Ulotaront

Ulotaront
Clinical data
Other names	SEP-363856; SEP363856; SEP-856; SEP856
Identifiers
	IUPAC name 1-[(7S)-5,7-dihydro-4H-thieno[2,3-c]pyran-7-yl]-N-methylmethanamine;
CAS Number	1310426-33-5;
PubChem CID	89532783;
ChemSpider	61321168;
UNII	3K6270MG59;
KEGG	D12474;
ChEBI	CHEBI:228346;
Chemical and physical data
Formula	C9H13NOS
Molar mass	183.27 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNC[C@H]1C2=C(CCO1)C=CS2;
	InChI InChI=1S/C9H13NOS/c1-10-6-8-9-7(2-4-11-8)3-5-12-9/h3,5,8,10H,2,4,6H2,1H3/t8-/m0/s1; Key:ABDDQTDRAHXHOC-QMMMGPOBSA-N;

Ulotaront (INNTooltip International Nonproprietary Name; developmental codes SEP-363856, SEP-856) is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis. The medication was discovered in collaboration between PsychoGenics Inc. and Sunovion Pharmaceuticals (which was subsequently merged into Sumitomo Pharma) using PsychoGenics' behavior and AI-based phenotypic drug discovery platform, SmartCube.

Ulotaront is in phase III clinical trial for schizophrenia, phase II/III for generalized anxiety disorder and major depressive disorder, and discontinued for narcolepsy and psychotic disorders.

Research has shown that ulotaront results in a greater reduction from baseline in the PANSS total score than placebo. Treatment with ulotaront, as compared with placebo, was also associated with an improvement in sleep quality. Ulotaront was awarded a Breakthrough Therapy designation due to its increased efficacy and greatly reduced side effects compared to current treatments.